Subscribe to RSS
DOI: 10.1055/s-2005-864099
© Georg Thieme Verlag KG Stuttgart · New York
No Relevant Interaction with Alprazolam, Caffeine, Tolbutamide, and Digoxin by Treatment with a Low-Hyperforin St John’s Wort Extract
Publication History
Received: June 30, 2004
Accepted: October 30, 2004
Publication Date:
27 April 2005 (online)
Abstract
We evaluated the pharmacokinetic interaction between a low-hyperforin St John’s wort (SJW) extract and alprazolam, caffeine, tolbutamide, and digoxin. Previous reports on other SJW products had shown remarkably decreased plasma concentrations of certain co-medicated drugs, which was attributed to an inducing effect of SJW on cytochrome P-450 (CYP) and p-glycoprotein (p-gp) activity. Two randomised, placebo-controlled studies were performed with 28 healthy volunteers (age 18 - 55 years) in each study. In study A, single doses of alprazolam (1 mg; substrate of CYP3A4) and caffeine (100 mg; CYP1A2) were given on days 1 and 11. In study B, single doses of tolbutamide (500 mg, days 1 and 11; CYP2C9) and multiple doses of digoxin (0.75 mg on days -2 and -1, 0.25 mg/die on days 1 to 11; p-gp) were given. The participants received SJW (Esbericum® capsules; 240 mg/die of extract, 3.5 mg hyperforin) or placebo on days 2 to 11. Blood for pharmacokinetic analysis was drawn on days 1 and 11. No statistically significant differences were found in the primary kinetic parameter, AUC0 - 24, of alprazolam, caffeine (AUC0 - 12), paraxanthine, tolbutamide, 4-hydroxytolbutamide, and digoxin between the placebo group and the SJW group at the end of the study. The SJW-induced change in AUCs was less than 12 % of the initial median AUC of the participants in studies A and B, thus clinically irrelevant. On day 11, trough concentrations were 2.0 (range 0.6 - 4.1) μg/L and 1.0 (0.2 - 3.9) μg/L for hypericin and pseudohypericin, respectively, whereas hyperforin concentrations were below the quantification limit (< 1 μg/L). Kinetics of investigated probe drugs were only marginally influenced by concomitant treatment with Esbericum® capsules. This may be due in particular to the low hyperforin plasma concentration as this SJW component has been shown to activate the PXR receptor which regulates expression of CYP3A4 and p-gp. Our findings corroborate the view that reports about interactions of other SJW extracts seem not to be predictive for the product we studied.
Key words
St. John’s wort - Hypericum perforatum - Clusiaceae - interaction - clinical trial - drug safety
References
- 1 Linde K, Mulrow C D. St John’s wort for depression. Cochraine Database Syst Rev. 2000; 2 CD000448
- 2 Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999; 66 338-45
- 3 Perloff M D, von Moltke L L, Störmer E, Shader R I, Greenblatt D J. Saint John’s wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol. 2001; 134 1601-8
- 4 Mai I, Krüger H, Budde K, Johne A, Brockmöller J, Neumayer H H. et al . Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharm Ther. 2000; 38 500-2
- 5 Bolley R, Zulke C, Kammerl M, Fischereder M, Kramer B K. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s wort. Transplantation. 2002; 73 1009
- 6 Johne A, Schmider J, Brockmöller J, Stadelmann A M, Störmer E, Bauer S. et al . Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J Clin Psychopharmacol. 2002; 22 46-54
- 7 Piscitelli S C, Burstein A H, Chaitt D, Alfaro R M, Lalloon J. Indinavir concentrations and St. John’s wort. Lancet. 2000; 355 547-8
- 8 Wang Z, Hamman M A, Huang S M, Lesko L J, Hall S D. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002; 71 411-3
- 9 Meier B. Comparing phytopharmaceuticals: the example of St John’s wort. Adv Ther. 2001; 18 35-46
- 10 Bundesanzeiger . Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln: Aufbereitungsmonographie der Kommission E, Hyperici herba (Johanniskraut). BAnz Nr. 43, 02.03.1989
- 11 Bauer S, Störmer E, Graubaum H J, Roots I. Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. Chromatogr B Biomed Sci Appl. 2001; 765 29-35
- 12 Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C. et al . Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics. 2002; 12 101-9
- 13 Friede M, Liske E, Wüstenberg P. Therapeutic effects of Hypericum perforatum in the treatment of depressive disorders. J Cereb Blood Flow Metab. 1999; 19 (suppl. 1) 116
- 14 Bernhardt M, Liske E. Antidepressive Therapie mit Johanniskraut-Extrakt unter besonderer Berücksichtigung von zwei unterschiedlichen Dosierungsschemata. Jatros Neurologie. 1996; 12 43-8
- 15 Zhou S, Chan E, Pan S Q, Huang M, Lee E J. Pharmacokinetic interactions of drugs with St. John’s wort. Psychopharmacol. 2004; 18 262-76
- 16 Wang Z, Gorski J C, Hamman M A, Huang S M, Lesko L J, Hall S D. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001; 70 317-26
- 17 Uehleke B, Mueller S C, Woehling H, Petzsch M, Riethling A -K. et al . Interaction of St. John’s wort with digoxin in relation to dosage and formulation. Phytomedicine. 2000; 7 (suppl. II) 20
- 18 Loyda R, Gruber K. Safety and tolerability of different Hypericum extracts. Phytomedicine. 2000; 7 (suppl. II) 20
- 19 Obach R S. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000; 294 88-95
- 20 Wentworth J M, Agostini M, Love J, Schwabe J W, Chatterjee V K. St. John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol. 2000; 166 R11-6
Dr. rer. nat. Michael Friede
Schaper & Bruemmer GmbH & Co. KG
Bahnhofstr. 35
38259 Salzgitter
Germany
Phone: +49-5341-307 560
Fax: +49-5341-307 524
Email: michael.friede@schaper-bruemmer.de